Sun Pharma Q4 Preview: PAT may grow 6% YoY; domestic business to drive revenue
Sun Pharma
is likely to see high single-digit growth in its bottom line in the fourth quarter on the back of continued outperformance in the domestic business. According to an average estimate of five brokerages, revenue is expected to grow 9% year-on-year (YoY).
Meanwhile, net profit for the reporting quarter will lag the revenue as an average of five estimates showed 6% YoY growth.
Analysts are building in $500 million US sales in 4QFY25, primarily due to higher gRevlimid sales. Meanwhile, gross margins are seen declining 30 bps QoQ to 79.7% due to lower milestone income.
For the specialty business, there is 20% YoY growth expectation at $325 million for 4Q owing to steady execution.
Here's what brokerages expect from Sun Pharma's Q4
Kotak Equities
We expect Sun Pharma's 4QFY25 overall sales to grow 8% YoY. For the global specialty business, we bake in a 17% QoQ sales decline to $308 million in 4QFY25, as specialty sales in 3QFY25 had inventory buildout and seasonality benefit. We build in a 9% YoY growth in India and a 9% YoY growth in RoW/EMs for 4QFY25.
We expect Sun Pharma's 4QFY25 gross margins to decline 30 bps QoQ to 79.7% due to lower milestone income. We bake in R&D spends at 7.7% of sales in 4QFY25 (+150 bps QoQ). On the EBITDA front, we factor in a 12% YoY growth to Rs34.7 bn, with an EBITDA margin decline of 390 bps QoQ to 26.8% due to higher R&D spend.
Motilal Oswal
Expect DF sales to grow 13% YoY for the quarter. Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets. Factors to drive consistent growth in branded generics in emerging/ROW markets. Any further progress on products in Amplitude basket.
YES Securities
Revenue decline seen as Q3 had one-off milestone income in ROW markets coupled with sequential fall in domestic business. US to inch up 2% QoQ on likely better Taro numbers (based on historical pattern). Higher R&D vs Q3 to dampen margin QoQ.
Nuvama
We build Sun Pharma's revenue to grow by 9% YoY as domestic business continues its outperformance at 10%. We build US revenue at $503 million and global specialty business at $335 million, with dermatology product sales seeing improvement. R&D spend is expected to be at 6.4% of the sales. We estimate EBITDA/PAT to grow by 22%/4% YoY with EBITDA margins at 28.4% for Q4FY25.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
Reliance Industries shares tumble: Why the conglomerate stock dropped 3% despite reporting record profit
Reliance Industries (RIL) fell 2.7% to Rs 1,436.85 on the BSE on Monday, despite the company posting its highest-ever quarterly profit of Rs 30,783 crore for Q1FY26. The strong earnings were boosted by a one-time gain from the Rs 8,924 crore sale of its stake in Asian Paints and lower interest and tax outgo. However, multiple brokerages flagged underwhelming operational performance across key segments Retail and Oil-to-Chemicals (O2C),which weighed on investor sentiment, ET reported. Reliance Industries shares declined by 3.24% on Monday, closing at Rs 1,428.20, down Rs 47.80, despite the company reporting its highest-ever quarterly profit. Jefferies noted that consolidated EBITDA was 3% below its estimate, with the O2C and Retail segments falling short by 5% and 4% respectively. It maintained a Buy rating with a price target of Rs 1,726 but highlighted that Retail growth was muted at just 8% year-on-year, impacted by slower electronics sales due to early monsoon and slower expansion. Emkay also reported a miss in EBITDA and adjusted profit by 5% and 7%, respectively. It blamed a 6% and 5% miss in O2C and Retail segment EBITDA for the underperformance. Motilal Oswal pointed out that Reliance Retail's operational EBITDA missed its estimate by 7%, as revenue growth came in at 11% against an expected 16%. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo JPMorgan noted the deceleration in retail growth and while retaining an Overweight rating, raised its target price to Rs 1,695, ET reported. The O2C business too disappointed, with consolidated EBITDA down 4% quarter-on-quarter, missing estimates by 8%, according to Motilal Oswal. Turnaround activities and a planned shutdown impacted output, said Nuvama, though analysts remain hopeful as global refining margins improve. Amid the mixed numbers, Reliance Jio emerged as a bright spot. EBITDA rose 5% quarter-on-quarter, beating estimates by 2%, supported by cost control and subscriber additions. ARPU rose to Rs 208.8, and the telecom arm added 9.9 million users. Analysts including praised Jio's performance, contrasting it with retail sluggishness and modest O2C recovery. Despite the challenges, RIL management remains optimistic, reaffirming its goal to double EBITDA by 2029, with Retail and Jio expected to double earnings in 3–4 years. Focus also remains on RIL's new energy push, expected to become a multidecade growth engine. Brokerages expect a 10GW module-to-polysilicon facility to boost earnings by FY26. Prabhudas Lilladher upgraded the stock to Accumulate, assigning Rs 111 per share to the energy vertical. Most brokerages maintained bullish ratings with targets ranging from Rs 1,500 (Macquarie) to Rs 1,767 (Nuvama), but some warned of short-term stock moderation. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Mint
9 hours ago
- Mint
Mutual funds boost holding in Suzlon Energy to an all-time high in June quarter
Mutual funds increased their bets on Suzlon Energy in the June quarter, as the latest shareholding data reveals that domestic fund houses collectively picked up an additional 1.07% stake in the wind energy company during the period. As of the end of June 2025, 30 mutual funds collectively held a 5.24% stake in Suzlon Energy, equivalent to 7.18 crore shares. This marks a notable increase from 4.17% at the end of the March quarter and 3.82% in Q1FY25, according to BSE shareholding data. The data also shows that Motilal Oswal Midcap Fund now holds a 1.03% stake in the company—a new addition, as the fund had no holdings in Suzlon at the end of March. Meanwhile, the Life Insurance Corporation of India (LIC) continues to hold a 1.02% stake. Retail investors also slightly increased their holdings by 0.1% to 55.1%, while promoters trimmed their stake to 11.7% from 13.3% in Q1FY25. Suzlon has remained on investors' radar in recent months due to positive brokerage views and multiple orders. Motilal Oswal, for instance, recently issued a 'buy' rating with a target price of ₹ 82 per share. The brokerage's optimism is driven by the expected adoption of the Revised List of Models and Manufacturers (RLMM) local content draft notification by Q2FY26, strong order prospects, the gradual phase-out of the ISTS waiver over the next four years, and an increasing share of EPC projects in the order book. Discussions with industry participants suggest that the RLMM notification—mandating local content in key wind turbine components—is likely to be formally implemented in Q2FY26. Motilal Oswal believes that Suzlon is well-positioned to benefit from favorable regulatory developments, a growing order book offering strong revenue visibility, and operational gains through proactive land acquisition and EPC expansion. Earlier, Anand Rathi also noted that Suzlon's 5.6 GW order book, which is 3.6x its FY25 execution volume, provides long-term growth visibility and ensures a steady pipeline of projects. It also reinitiated coverage with a 'buy' rating and a target price of ₹ 81 apiece. Despite these positive projections, the stock has come under pressure in recent months due to broader market weakness, declining 12% from its recent highs. However, Suzlon remains a strong long-term performer, with shares rising 277% over the past two years and over 1,200% in the last five years. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before taking any investment decisions.
&w=3840&q=100)
Business Standard
9 hours ago
- Business Standard
Brokerages remain divided on RBL Bank after Q1 result; check recommendation
RBL Bank shares slipped 3.2 per cent, logging an intraday low at ₹254.7 per share on BSE. The selling pressure on the counter came after the company posted Q1 results. At 11:19 AM, RBL Bank share price was trading 1.65 per cent lower at ₹258.8 per share on the BSE. In comparison, the BSE Sensex was up 0.48 per cent at 82,148.37. The company's market capitalisation stood at ₹15,765.65 crore. The 52-week high of the stock was at ₹272.9 per share, and the 52-week low of the stock was at ₹146 per share. What should investors do with RBL Bank shares post Q1FY26 results? Motilal Oswal has maintained a 'Buy' with a target price of ₹290 per share. According to the brokerage, the bank reported a beat on earnings, with margins sharply moderating due to the repo rate cuts. Deposits grew 2 per cent quarter-on-quarter (Q-o-Q), with the current account savings account (CASA) ratio moderating to 32.5 per cent. Advances also increased 2 per cent Q-o-Q, with the bank expecting it to grow in the mid-teens, with a mid-to-high teen growth in wholesale advances. Post the results, Motilal Oswal fine-tuned its earnings per share (EPS) estimates and projected an FY27E return on asset/ return on equity (RoA/RoE) of 1.07 per cent/11.4 per cent. Incred Equities has also iterated 'Add' with an upward revision in target to ₹290 per share from ₹260. The brokerage believes that moderating the microfinance institutions (MFI) Special Mention Account (SMA) book is comforting and improves visibility of 200 basis points (bp) credit costs for FY26F. However, ICICI Securities has downgraded RBL Bank to 'Hold' from 'Add' with a revised target to ₹250 from ₹210. "RBL Bank reported a weak Q1 performance, with a sharp 40 bps Q-o-Q decline in net interest margin (NIM), double-digit drop in net interest income (NII), and no improvement in slippages (new bad loans)," the brokerage note read. Check List of Q1 results today RBL Bank Q1 results The bank posted a 46 per cent year-on-year (Y-o-Y) decline in its net profit to ₹200 crore for the quarter ended June 30, 2025, compared to ₹371.5 crore a year ago. The Net Interest Income (NII) of the lender fell 13 per cent Y-o-Y to ₹1,481 crore from ₹1,700 crore, and declined 5 per cent sequentially from ₹1,563 crore in the March 2025 quarter. Net Interest Margin (NIM) for the quarter stood at 4.50 per cent, as compared to 4.89 per cent in Q4FY25, and 5.67 per cent in the year-ago period. Other income of the bank rose by 33 per cent to ₹1,069 crore during the quarter, against ₹805 crore in the same period last year. In Q4FY25, other income stood at ₹1,000 crore.
